@article{PAR00006544,
  title = {{C}ost-effectiveness analysis of {T}rastuzumab ({H}erceptin) in {HER}2-overexpressed metastatic breast cancer},
  author = {{P}erez-{E}llis, {C}. and {G}oncalves, {A}. and {J}acquemier, {J}. and {M}arty, {M}. and {G}irre, {V}. and {R}oche, {H}. and {B}rain, {E}. and {M}oatti, {J}ean-{P}aul and {V}iens, {P}. and {L}e {C}orroller-{S}oriano, {A}. {G}.},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjective: {I}n women with {H}uman {E}pidermal growth {R}eceptor 2 ({HER}2)-positive {M}etastatic breast cancer ({MBC}), {T}rastuzumab has become the standard of care but previous studies have raised doubts about its economic acceptability. {W}e carried out the first cost-effectiveness study for {T}rastuzumab in {MBC} patients, in {F}rance, that is based on observed resource use and outcomes in clinical practice. {M}ethods: {W}e retrospectively analyzed 47 {HER}2-positive {MBC} patients in a before-and-after design study. {N}ineteen patients did not receive {T}rastuzumab ("before" {T}rastuzumab introduction in clinical practice) and 28 patients received {T}rastuzumab (the "after" population). {D}irect medical costs were estimated oil the basis of the physical quantities reported in the patient medical records, for the period from first metastatic progression until death or date of patient last news. {M}onetary values (2002 {F}rench francs) were attributed to these quantities oil the basis of unit costs and incremental cost-effectiveness ratios were calculated. {R}esults: {I}n the {T}rastuzumab group, median overall survival was significantly higher (37 months vs. 19 months in the non-{T}trastuzumab group, {P} = 0.001) but total treatment costs were 3 times higher ((sic)39,608 vs. (sic)12,795). {T}he cost per additional life-year saved by {T}rastuzumab treatment was estimated to be (sic)27,492 (95% confidence interval: (sic)20,964-(sic)34,020/year of life [boot-strapped estimation]). {C}onclusions: {O}ur data suggest that despite its high unit price, {T}rastuzumab should be considered cost-effective in {MBC} patients to the extent that its incremental cost per life-year saved remains lower than gross domestic product per capita in countries like {F}rance.},
  keywords = {metastatic breast cancer ; cost-effectiveness analysis ; {T}rastuzumab ; ({H}erceptin)},
  booktitle = {},
  journal = {{A}merican {J}ournal of {C}linical {O}ncology. {C}ancer {C}linical {T}rials},
  volume = {32},
  numero = {5},
  pages = {492--498},
  ISSN = {0277-3732},
  year = {2009},
  DOI = {10.1097/{COC}.0b013e3181931277},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00006544},
}